Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases


October 25, 2022

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis


October 3, 2022

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America


September 28, 2022

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx™ for Treatment of Acute Myocarditis


August 3, 2022

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting


June 29, 2022

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT


June 27, 2022

Cardiol Therapeutics Announces At-The-Market Equity Offering Program


June 9, 2022

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors


May 19, 2022

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis


May 17, 2022

2025 Cardiol Therapeutics. All right reserved.